Clinical, radiographic characteristics and immunomodulating changes in neuromyelitis optica with extensive brain lesions

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Cheng, Chen ^a   Jiang, Ying ^a   Chen, Xiaohong ^a   Dai, Yongqiang ^a   Kang, Zhuang ^a   Lu, Zhengqi ^a   Peng, Fuhua ^a   Hu, Xueqiang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Aquaporin 4; C reactive Protein; Complement; Erythrocyte sedimentation rate; Extensive brain lesions; Magnetic resonance imaging; Neuromyelitis optica

Indexed keywords

AQUAPORIN 4; AZATHIOPRINE; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; METHYLPREDNISOLONE; PREDNISONE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADULT; ARTICLE; ATAXIA; BULBAR PARALYSIS; CHINA; COMA; COMPLEMENT BLOOD LEVEL; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEADACHE; HICCUP; HOMONYMOUS HEMIANOPIA; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NARCOLEPSY; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PLASMAPHERESIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGNOSIS; RELAPSE; SEIZURE; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; AQUAPORIN 4; BRAIN; BRAIN INJURIES; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; COMPLEMENT SYSTEM PROTEINS; DIFFUSION TENSOR IMAGING; DISABILITY EVALUATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; NEUROMYELITIS OPTICA; OLIGOCLONAL BANDS; RETROSPECTIVE STUDIES;

EID: 84879835431     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-72     Document Type: Article

References (36)

1. Wingerchuk DM. Diagnosis and treatment of neuromyelitis optica. Neurologist 2007, 13(1):2-11. 10.1097/01.nrl.0000250927.21903.f8, 17215722.
2. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202(4):473-477. 10.1084/jem.20050304, 2212860, 16087714.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364(9451):2106-2112. 10.1016/S0140-6736(04)17551-X, 15589308.
4. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006, 63(3):390-396. 10.1001/archneur.63.3.390, 16533966.
5. Chan KH, Tse CT, Chung CP, Lee RL, Kwan JS, Ho PW, Ho JW. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol 2011, 68(11):1432-1439. 10.1001/archneurol.2011.249, 22084126.
6. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006, 63(7):964-968. 10.1001/archneur.63.7.964, 16831965.
7. Matsushita T, Isobe N, Matsuoka T, Ishizu T, Kawano Y, Yoshiura T, Ohyagi Y, Kira J. Extensive vasogenic edema of anti-aquaporin-4 antibody-related brain lesions. Mult Scler 2009, 15(9):1113-1117. 10.1177/1352458509106613, 19625334.
8. Kim W, Kim SH, Lee SH, Li XF, Kim HJ. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler 2011, 17(9):1107-1112. 10.1177/1352458511404917, 21543554.
9. Matsushita T, Isobe N, Matsuoka T, Shi N, Kawano Y, Wu XM, Yoshiura T, Nakao Y, Ishizu T, Kira JI. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler 2009, 15(7):834-847. 10.1177/1352458509104595, 19465451.
10. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125(Pt 7):1450-1461.
11. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, Mandler RN, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130(Pt 5):1194-1205.
12. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, Takahashi T, Nakashima I, Takahashi H, Itoyama Y. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007, 130(Pt 5):1224-1234.
13. Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, Lennon VA. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69(24):2221-2231. 10.1212/01.WNL.0000289761.64862.ce, 17928579.
14. Ramos-Casals M, Campoamor MT, Chamorro A, Salvador G, Segura S, Botero JC, Yague J, Cervera R, Ingelmo M, Font J. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 2004, 13(10):777-783. 10.1191/0961203304lu1080oa, 15540510.
15. Ramos-Casals M, Brito-Zeron P, Yague J, Akasbi M, Bautista R, Ruano M, Claver G, Gil V, Font J. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2005, 44(1):89-94.
16. Alexander EL, Provost TT, Sanders ME, Frank MM, Joiner KA. Serum complement activation in central nervous system disease in Sjogren's syndrome. Am J Med 1988, 85(4):513-518. 10.1016/S0002-9343(88)80087-1, 3177398.
17. Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 2007, 46(8):1359-1362.
18. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340(6):448-454. 10.1056/NEJM199902113400607, 9971870.
19. Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician 1999, 60(5):1443-1450.
20. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003, 111(12):1805-1812. 161431, 12813013.
21. Giovannoni G, Thorpe JW, Kidd D, Kendall BE, Moseley IF, Thompson AJ, Keir G, Miller DH, Feldmann M, Thompson EJ. Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry 1996, 60(1):20-26. 10.1136/jnnp.60.1.20, 486184, 8558145.
22. Aksungar FB, Topkaya AE, Yildiz Z, Sahin S, Turk U. Coagulation status and biochemical and inflammatory markers in multiple sclerosis. J Clin Neurosci 2008, 15(4):393-397. 10.1016/j.jocn.2007.02.090, 18258432.
23. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66(10):1485-1489. 10.1212/01.wnl.0000216139.44259.74, 16717206.
24. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33(11):1444-1452. 10.1212/WNL.33.11.1444, 6685237.
25. Paty DW, Davis FA. Patient selection and criteria. Arch Neurol 1983, 40(11):701. 10.1001/archneur.1983.04050100041015, 6625979.
26. Given CN, Stevens BS, Lee C. The MRI appearance of tumefactive demyelinating lesions. AJR Am J Roentgenol 2004, 182(1):195-199. 10.2214/ajr.182.1.1820195, 14684539.
27. Eichel R, Meiner Z, Abramsky O, Gotkine M. Acute disseminating encephalomyelitis in neuromyelitis optica: closing the floodgates. Arch Neurol 2008, 65(2):267-271. 10.1001/archneurol.2007.59, 18268199.
28. Magana SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, Shuster E, Kantarci OH, Lucchinetti CF, Weinshenker BG. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009, 72(8):712-717. 10.1212/01.wnl.0000343001.36493.ae, 19237699.
29. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Shiga Y, Kanaoka C, Fujimori J, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007, 130(Pt 5):1235-1243.
30. Masdeu JC, Moreira J, Trasi S, Visintainer P, Cavaliere R, Grundman M. The open ring. A new imaging sign in demyelinating disease. J Neuroimaging 1996, 6(2):104-107.
31. Tenembaum S, Chitnis T, Ness J, Hahn JS. Acute disseminated encephalomyelitis. Neurology 2007, 68(16 Suppl 2):S23-S36.
32. Politi M, Papanagiotou P, Grunwald IQ, Roth C, Reith W. Acute disseminated encephalomyelitis. Radiologe 2008, 48(6):553-559. 10.1007/s00117-008-1693-y, 18478196.
33. Schaefer PW, Grant PE, Gonzalez RG. Diffusion-weighted MR imaging of the brain. Radiology 2000, 217(2):331-345.
34. Zhang B, Jiang Y, Yang Y, Peng F, Hu X. Correlation between serum thyroxine and complements in patients with multiple sclerosis and neuromyelitis optica. Neuro Endocrinol Lett 2008, 29(2):256-260.
35. Doi H, Matsushita T, Isobe N, Matsuoka T, Minohara M, Ochi H, Kira JI. Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody. Mult Scler 2009, 15(3):304-310. 10.1177/1352458508099139, 19028829.
36. Matsuoka T, Matsushita T, Kawano Y, Osoegawa M, Ochi H, Ishizu T, Minohara M, Kikuchi H, Mihara F, Ohyagi Y, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007, 130(Pt 5):1206-1223.